March 19, 2009 - Sanofi-aventis said yesterday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 10-3 in favor of the approval of Multaq (dronedarone) to treat patients with non-permanent atrial fibrillation (AF).
As demonstrated in the ATHENA trial, the maker said Multaq is the only anti-arrhythmic drug to have shown in a clinical study a significant reduction in morbidity and mortality in patients with atrial fibrillation/atrial flutter (AFL) or a recent history of these conditions.
The FDA is not bound by the committee’s recommendation, but it takes its advice into consideration when reviewing new drug applications.
Atrial fibrillation is the leading cause of hospitalization for arrhythmia in the U.S. and represents one-third of hospitalizations for arrhythmia in Europe. Hospitalization due to AF has increased dramatically (two-to-three fold) in recent years in the U.S. Atrial fibrillation is a complex disease that increases the risk of stroke up to five-fold, worsens the prognosis of patients with cardiovascular risk factors, and doubles the risk of mortality. There are approximately 2.5 million Americans and 4.5 million people in the European Union with atrial fibrillation and it is emerging as a growing public health concern due to an aging population.
Multaq is an investigational treatment discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 6,700 patients. The company said Multaq is one of the major therapeutic innovations in atrial fibrillation in the last 20 years. Multaq has been granted a priority review by the FDA and a registration dossier is also under regulatory review by the European Medicines Agency (EMEA).
For more information, visit: www.sanofi-aventis.us, www.sanofi-aventis.com.
July 10, 2024 
